Eisai's Halaven stumbles at NICE efficacy hurdle
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, will issue preliminary draft guidance 20 July 2011 declining to recommend Eisai's Halaven (eribulin) for patients with locally advanced metastatic breast cancer whose disease has progressed after two chemotherapeutic regimens for advanced disease. NICE had originally planned to publish the guidance on 19 July but delayed publication until 20 Julybecause of confusion with Eisai over the publication date.